Q32 Bio Inc. (QTTB) stock
Close on Nov 13, 2026Market cap $259.29MP/E –Yield –
Q32 Bio Inc. reported revenue of $53.74M for fiscal 2025. Free cash flow was -$33.54M. At the latest close the market valued the company at $259.29M.
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Sep 30, 2026
Valuation
- Market cap
- $259.29M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 0.90
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $53.74M
- Net income
- $32.25M
- EPS, diluted
- $2.42
- Free cash flow
- -$33.54M
- Book value per share
- $8.46
- Diluted shares
- 34M
Trading
- Next earnings
- Mar 9, 2027 (estimated, before the open)
- Previous close
- $8.82
- Open
- $8.83
- Day's range
- $8.45 – $8.95
- Volume
- 243,849
- Average volume (20 days)
- 373,647
- Beta (5 years)
- 0.67
- 52-week range
- $1.91 – $23.57
- RSI (14 days)
- 44.6
- Volatility (1 year)
- 170.2%
- Relative volume
- 0.22×
- WACC
- 8.5%
On 2 of our idea lists: Net-nets, More cash than they're worth
Market cap history
Month-end market cap since 2018, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 13, 2026. The S&P 500 is measured by the SPY fund.
| Period | QTTB | S&P 500 | Difference | QTTB per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +8.1% | -3.0% | +11.1 pts | ||
| 3 months | -43.3% | -2.8% | −40.5 pts | ||
| Year to date | +162.3% | +11.5% | +150.9 pts | ||
| 1 year | +294.1% | +13.5% | +280.7 pts | ||
| 3 years | -53.0% | +77.7% | −130.7 pts | -22.3% | +21.1% |
| 5 years | -91.5% | +72.6% | −164.1 pts | -39.0% | +11.5% |
Ten years at a glance
Fiscal years 2016 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Q32 Bio filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Update
- Update
- Results
- News
- Update
About Q32 Bio
Pharmaceutical Preparations
Q32 Bio Inc. is a clinical-stage biotechnology company that develops biological therapies to restore immune balance in patients affected by autoimmune and inflammatory diseases. Its primary product candidate is bempikibart, a fully human monoclonal antibody antagonist that blocks signaling driven by interleukin-7 and thymic stromal lymphopoietin. The company develops bempikibart for autoimmune disorders, focusing specifically on individuals with alopecia areata. It has also created a proprietary tissue-targeted complement inhibitor platform that includes pre-clinical therapies such as ADX-096. Because its product candidates remain in development, the company has not commercialized products or established a commercial customer base.
Company profile, executives and historyQ32 Bio stock: common questions
What is Q32 Bio's stock price?
QTTB closed at $8.71 on Nov 13, 2026, down 1.25% on the day. Over the past 52 weeks it traded between $1.91 and $23.57.
What is Q32 Bio's market cap?
Q32 Bio was worth $259.29M at the close on Nov 13, 2026: the share price times the diluted shares outstanding.
How much revenue does Q32 Bio make?
Q32 Bio reported revenue of $53.74M for fiscal 2025.
Does Q32 Bio pay a dividend?
No. Q32 Bio has not paid a cash dividend over the last twelve months.
When does Q32 Bio report earnings next?
Q32 Bio is expected to report Q4 FY2026 results on Mar 9, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has QTTB stock performed over the past year?
Including dividends, QTTB returned +294.1% over the past year, against +13.5% for the S&P 500.
How many QTTB shares are sold short?
6M shares were sold short at the latest FINRA report, 26.43% of the float, or 12.1 days of average trading volume.
Who are Q32 Bio's competitors?
Companies most similar to Q32 Bio by business, industry and size include NKTR, ROIV, CUE, EQ, XLO.
See a number that looks wrong?